Pfizer headquarters, in a conference room.
A very serious meeting is going on.
Of course, although it was called a meeting, it was more like an interrogation.
Pfizer CEO John Young sat in the front seat, looking directly at Skana Slaoui sitting opposite.
"Dr. Slavi, the company has given you a lot of resources and funding, not to allow you to develop a drug that cannot even pass the first phase of clinical trials."
John Young's tone was very calm, but for Skarna Slavi, who was sitting opposite him, it was full of pressure.
After all, it can be called the largest pharmaceutical company in the world. As the president of such a company, John Young is ruthless enough when he should be ruthless.
Skana Slavi took a deep breath, calmed down his emotions, and then said: "President, I admit that in this research and development, I was a little eager for quick success."
"Of course, that doesn't mean our results are a complete failure."
He regained his composure and then said: "The main problem with PEFF is that it causes a higher degree of platelet activation."
"Now we only need to continue to experiment with the principle of increasing the degree of platelet activation, and then modify it according to this principle to solve this problem and retain the original thrombolytic effect of PEFF."
"Mr. President, you should also know how excellent the actual thrombolytic effect of PEFF is."
John Yang smiled: "It can both dissolve thrombosis and coagulate thrombosis."
"Dr. Slavi, the drug you developed is quite ironic."
Then he said "tsk" again, "Tell me, why did the problem occur in the first phase of the clinical trial?"
Everyone present could hear the pity in his words.
This kind of medicine is almost like planned obsolescence, and it is deeply favored by companies like theirs.
It's just a pity that they were unlucky and encountered this kind of thing during the first phase of clinical trials.
In fact, it was mainly because the patient who had the problem had a higher platelet activation level, and coupled with the impact of PEFF, it led to this clinical accident.
As long as they are a little bit lucky and these clinical volunteers do not have this kind of situation, with their Pfizer influence, they can easily get this drug successfully launched. Even if problems arise again, they will be able to cover up similar news. .
Anyway, as long as it can be listed on the market, it can make money.
Among their other drugs that are already on the market, there are more or less such drugs that have unspecified side effects that may cause life-threatening side effects.
Finally, John Yang sat up straight and said to Skana Slavi: "Okay, Dr. Slavi, no matter what, you are also our chief scientist and have made many great contributions to the company."
"This failure should be regarded as a lesson. I also hope that, as you just said, PEFF can be modified and then it can be put on the market again."
"At least, the stock price brought about by this incident has made our shareholders make some money, so they are not too dissatisfied with you, but I still hope that you can prove that you are a Pfizer company next time The capabilities of the chief scientist.”
Skana Slavi breathed a sigh of relief, and a smile appeared on his face: "Don't worry, I won't let the directors down."
He had actually expected this result. After all, he had made so much money for the company, so it was impossible to fire him because of this incident. As for the clinical volunteer, it was nothing more. It's just a lawsuit. The last thing their company is afraid of is a lawsuit. Anyway, the clinical volunteers have signed an agreement, not to mention that these volunteers are paid, and they will only win if there is a lawsuit.
"Okay, that's the end of today's meeting. Let's adjourn."
John Yang announced, and then he stood up first and was about to leave, but at this moment, the door of the conference room suddenly opened, his assistant ran in, and then spoke a few words in his ear.
Then the people present could see their president's expression gradually getting worse.
No one dared to leave for a while.
John Yang glanced at the people present, then sat back in his seat and said: "The meeting continues to begin."
Then he stared at Skana Slavi again and said, "What is your relationship with Kingsley Weir and Li Mu?"
Skana Slavi was stunned for a moment, a little confused.
"President, why...why do you suddenly ask this question?"
"Just answer first."
"I... I'm not very familiar with Li Mu. I just invited him to join us at Pfizer at the Max Planck Life Sciences Conference dinner. You know this. As for Kingsley Weir... uh... "
Under the gaze of the president, Skarna Slavi could only tell the story of the conflict between him and Kingsley Weir.
After learning that Skana Slavi's then-girlfriend was actually snatched away by this man named Kingsley Weir, everyone present wanted to laugh, but did not dare to laugh.
John Yang was silent for a moment. He only knew that there was a conflict between Skana Slavi and Kingsley Weir, but he did not expect that it was this conflict. For a moment, he didn't know what to say.
But in the end, he shook his head and motioned to the assistant next to him.
Then, the assistant nodded, and then said to everyone: "According to the latest information, the team of Li Mu and Kingsley Weir have developed a new type of thrombolytic drug, which they named RSCA. "
"This drug has a stronger thrombolytic effect than the fourth generation thrombolytic drugs. In addition, it can also form a film on the surface of insoluble fibrin, making it smoother and less likely to clot. stand up."
"In addition, according to the news, the biggest advantage of their new thrombolytic drug is that it is more specific and only targets the fibrin in the thrombus without dissolving the blood vessels and causing bleeding symptoms."
"What?!"
Skana Slavi's eyes widened immediately.
When the other researchers in the conference room heard the news, they couldn't sit still for a while.
"Can you actually develop this kind of thrombolytic drug?"
Anyone who has done some research on thrombolytic drugs is shocked at this time.
"And I remember that Kingsley Ware approached us and wanted to develop this drug, but we refused to cooperate with him because of you. I still remember that you called him a liar."
John Yang's brows gradually furrowed: "I hope you can give me an explanation for this matter!"
And Skana Slavi was already full of disbelief: "Impossible, absolutely impossible!"
…
"Pfizer's new drug fails, but the "liar's" new drug succeeds? 》
"The perfect thrombolytic drug, RSCA?" 》
"Li Mu's data analysis method regains its power, and perfect thrombolytic drugs set off a medical revolution"
"..."
As the paper about RSCA was published in "Cell", the effect of RSCA immediately caused a shock in the entire medical community, even worse than Pfizer's PEFF before.
After all, RSCA can be regarded as the most perfect thrombolytic drug based on its effects alone.
In the paper, people in the biomedical field once again saw the huge role of Li Mu's data analysis method, just like the special issue of The Lancet.
For a time, the entire medical community was shocked by the effects of RSCA.
…
Mayo Clinic, in Jason Leighton's office.
As a top cardiac surgeon, he was being interviewed by a news reporter.
"Hello, Dr. Layton."
A reporter from the New York Times said to Jason Layton with great respect that in this country, doctors and lawyers are the most respected professions, not to mention top doctors like Jason Layton.
"I believe you should be aware of the recent news about the failure of Pfizer's new thrombolytic drug, and about the so-called most perfect thrombolytic drug developed by the mathematical genius Li Mu."
"Of course, I have seen these two news." Jason Layton nodded.
The reporter smiled slightly and then asked: "I heard that in your operations, generally the need for thrombolytic drugs is relatively high. Is this true?"
Jason Layton laughed: "Of course, it's true."
"Thrombus-dissolving drugs are a necessary drug for cardiac surgery, because what you need to know is that once cardiac surgery is performed, it is very easy to form blood clots in the patient's body - or any surgery can easily lead to the formation of blood clots. Because during and after the operation, the human body will be in a state of stress, and the blood will be in a hypercoagulable state, mobilizing coagulation factors in the body, which will lead to blood clot problems."
"Especially in our cardiac surgery, problems caused by blood clots have always had an impact on our operations. Therefore, in our operations, the main purpose of cardiac angiography, cardiac CT, etc. is to detect whether there is The problem of blood clots.”
"So that's it!" The reporter nodded.
"So, what do you think of Pfizer's PEFF and Li Mu's RSCA? Will RSCA be successful?"
After thinking for a moment, Jason Layton said: "PEFF has nothing to say. This kind of thrombolytic drug is really ridiculous. A thrombolytic drug that can increase platelet activation is like wearing pants to go to the toilet. It is extremely stupid."
"As for RSCA... I don't know how to evaluate it at the moment, but if its effect is really as stated in the paper, I would like to say that this will be the favorite thrombolytic drug for cardiac surgeons like me. The thrombolysis is fast and efficient, and the most important thing is that the effect lasts for up to two years..."
"I would say there is no better thrombolytic drug than this."
"So, we just need to wait for the verification of clinical trials."
"Of course, psychologically, I believe it."
"Although I haven't met Li Mu in person, I feel in my heart that he is a magical person."
Jason Layton said with a smile.
Under the influence of Li Mu's paper, he had already developed admiration for this person he had never met.
When Jason Layton said this, the reporter also sighed with emotion, "Yes, he is indeed a magical person. As I just said, he is obviously a mathematical genius, but how can he be so omnipotent?"
Jason Layton nodded with deep understanding.
…
(End of chapter)
